Precision Biosciences Inc (DTIL): Capital Expenditures
$85.0K
Year ended 2025-12-31
$37.0K
Trailing 12 months to 2026-06-30
-70.5%
3-year compound annual growth
-55.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $85.0K | -66.0% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $250.0K | -87.2% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $1.96M | -41.0% | 2025-03-26, From 2023-01-01 |
| 2022-12-31 | $3.32M | -34.3% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $5.05M | +0.4% | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $5.03M | -79.6% | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | $24.67M | +72.8% | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | $14.28M | n/a | 2020-03-10, From 2018-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $85.0K | -66.0% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $0 | -100.0% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $607.0K | +237.2% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $133.0K | n/a |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.45M | -88.7% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $102.0K | -61.8% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $607.0K | -93.1% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $574.0K | -81.6% |
Compare DTIL, XFOR, CCCC, SCLX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗